RNA (recombinant [1,2-[m7Gm-p-[P(R)]-sp-p-G]]-capped human monophenol monooxygenase-specifying poly(A)-tailed messenger RBL002.4), inner salt
Melanoma
BioNTech RNA Pharmaceuticals GmbHvaccinePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 65/ 100
Competitive context
450 Active assets in the Melanoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Gm-Csf Ultimovacs ASA | Phase 4 | BBB |
Sargramostim Mayo Clinic | Phase 3 | BBB |
Cediranib M.D. Anderson Cancer Center | Phase 3 | BBB |
Ifa Craig L Slingluff, Jr | Phase 2 | BB |
Tebentafusp Immunocore Ltd | Phase 3 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →